# Personal Genome Diagnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/personal-genome-diagnostics

- Industry: Biotechnology
- Headquarters: Baltimore, US
- Website: www.personalgenome.com
- Total disclosed funding: $184M
- Latest round: Series C (Feb 10, 2021)
- Investors on record: 16

## About

Based in Maryland, US, and founded in 2010 Personal Genome Diagnostics Inc. is a developer of cancer genome testing products. In February 2021, Personal Genome Diagnostics Inc. raised USD 97.70 million in series C funding led by Cowen Investment Management, with participation from other new investors Catalio Capital Management, Kern Capital Management LLC, and Northpond Ventures.

The company's technologies and bioinformatics help in identifying tumor mutations with accuracy by identifying alterations in complex cancer genomes, enabling oncology researchers, drug developers, clinicians, and patients to address cancer-related genetic changes.

The company’s revenue is generated through the sale of PGDx’s elio™ oncology products to hospitals.

The company plans to expand the its tissue-based and liquid biopsy portfolio and support the expansion to accelerate therapy development.

## Funding rounds

- Series C, Feb 10, 2021, $98M — New Enterprise Associates, Windham Venture Partners, Rock Springs Capital, Cowen Investment Management, Sands Capital Alternatives, Innovatus Capital Partners, Northpond Ventures, Vensana Capital, Catalio Capital Management, Kern Capital Management LLC, PFM Health Sciences
- Series B, Oct 13, 2017, $65M — New Enterprise Associates, Bristol-Myers Squibb Company, Windham Venture Partners, Maryland Venture Fund, 3B Future Health Fund, Inova Strategic Investments, Co-win Healthcare Fund
- Series A, Oct 23, 2015, $20M — New Enterprise Associates, Windham Venture Partners

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B, Series C
- Windham Venture Partners (https://capitalatlas.ai/funds/windham-venture-partners) — Series A, Series B, Series C
- Bristol-Myers Squibb Company — Series B
- Maryland Venture Fund (https://capitalatlas.ai/funds/maryland-venture-fund) — Series B
- 3B Future Health Fund (https://capitalatlas.ai/funds/3b-future-health-fund) — Series B
- Inova Strategic Investments (https://capitalatlas.ai/funds/inova-strategic-investments) — Series B
- Co-win Healthcare Fund (https://capitalatlas.ai/funds/co-win-healthcare-fund) — Series B
- Rock Springs Capital — Series C
- Cowen Investment Management — Series C
- Sands Capital Alternatives (https://capitalatlas.ai/funds/sands-capital-alternatives) — Series C
- Innovatus Capital Partners (https://capitalatlas.ai/funds/innovatus-capital-partners) — Series C
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series C
- Vensana Capital (https://capitalatlas.ai/funds/vensana-capital) — Series C
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series C
- Kern Capital Management LLC — Series C
- PFM Health Sciences (https://capitalatlas.ai/funds/pfm-health-sciences) — Series C